ABSTRACT

Objective: The objective of this study was to evaluate the safety and effectiveness of the concurrent use of botulinum toxin type A and hyaluronic acid (HA) fillers in the context of face rejuvenation. The study examined the synergistic effects of various therapies in achieving a restorative appearance that is both clinically effective and aesthetically pleasing. Methodology: In order to investigate the efficacy of botulinum toxin type-A and hyaluronic acid filler in the process of facial rejuvenation, a randomised controlled trial was undertaken from September 22, 2022, to June 28, 2023. The study included a total of 100 participants who were separated into two groups. The control group consisted of 50 patients who had treatment solely with botulinum toxin type A, while the observation group comprised 50 patients who received both botulinum toxin type A and hyaluronic acid filler. The analysis encompassed an evaluation of clinical efficacy, safety, and patient satisfaction in order to provide a comparison between the two groups. Results: The findings of the research study revealed that the patients in the experimental group demonstrated a much higher success rate (60.11%) and reported greater satisfaction with their treatment compared to the patients in the control group (25.67%). Furthermore, it was noted that patients who were under surveillance had lower dosages of botulinum toxin type A. However, no significant disparities were found between the groups in terms of adverse effects, such as facial edoema and congestion. However, there were certain time intervals in which the control group exhibited a more favourable duration of effect. Significant statistical differences were seen at both the six-month and nine-month follow-up assessments. Conclusion: The efficacy of a combined treatment using botulinum toxin type-A and hyaluronic acid filler has been demonstrated to be a superior choice for face rejuvenation. The administration of this therapeutic intervention leads to prolonged efficacy, diminished dose demands, and heightened patient contentment in contrast to exclusive utilisation of botulinum toxin type A. In conclusion, the use of this integrated therapeutic approach yields enhanced clinical advantages.